Why Is Applied Therapeutics Stock Trading Higher Today? - Applied Therapeutics (NASDAQ:APLT)

Applied Therapeutics surges as FDA grants Priority Review to govorestat (AT-007) for Galactosemia treatment. If approved, it would be the first medication for Galactosemia. APLT also submits MAA to EMA, with a decision expected in Q4 2024. Private placement of $100 million.

Related Keywords

,European Medicines Agency ,Committee For Medicinal Products Human ,New Drug Application ,Priority Review ,Prescription Drug User Free Act ,Pediatric Rare Disease ,Priority Review Voucher ,Applied Therapeutic ,Marketing Authorization Application ,Classic Galactosemia ,Medicinal Products ,Applied Therapeutics ,Private Placement ,Advanz European ,